p16Ink4a in Bronchopulmonary Dysplasia in Children
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Other: Blood punction
- Registration Number
- NCT03540680
- Lead Sponsor
- Centre Hospitalier Intercommunal Creteil
- Brief Summary
The bronchopulmonary dysplasia (BPD) is a respiratory disease of the premature child which lead to a reduction of gas exchange surface and to a prolonged respiratory failure. This disease has morphologic and functional consequences at adulthood and is today considered to be an early determinant of respiratory diseases at adulthood.
The physiopathology of BPD is not well known. Several mechanisms could be involved especially a reparation failure favored by an increase of cellular senescence which is a permanent stop of cellular proliferation. The transcription factor 16 Ink4a, considered as a marker of aging, is one of the essential markers of senescence. Its increase during prematurity was shown at the blood cells of the cordon, but its involvement in BPD and its evolution in child are not yet studied.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 80
Premature(< 28 GA) neonates
- Alive neonate born at less than 28 gestational age
- Signed inform consent
Term neonates:
- Alive neonate born at least at 37 GA or more
- Signed inform consent
Child from 7 to 15 years old with BPD:
- Child from 7 to 15 years old
- Child with a BPD diagnosed
- Signed inform consent
Child from 7 to 15 years old without BPD:
- Child from 7 to 15 years old
- Child receiving a blood test
- Signed inform consent
Premature (< 28 GA) and term neonates:
-Congenital malformation
Child from 7 to 15 years old with BPD:
- Cystic fibrosis
- Evolutive cancer
- Chronic inflammatory disease
- Known anemia
- Refusal of participation of child or parental authority
Child from 7 to 15 years old without BPD:
- Other respiratory disease: severe asthma, cystic fibrosis, deficit AAT, bronchial dilatation
- Evolutive cancer
- Chronic inflammatory disease
- Known anemia
- Refusal of participation of child or parental authority
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Premature newborns Blood punction Blood punction on the cordon Term newborns (≥37GA) Blood punction Blood punction on the cordon Child between 7 and 15 years old with BPD Blood punction Blood punction Child between 7 and 15 years old without BPD Blood punction Blood punction
- Primary Outcome Measures
Name Time Method p16 expression Day 1 p16 expression measured by qPCR in newborns cord blood cells and in circulating leukocytes of children aged from 7 to 15
- Secondary Outcome Measures
Name Time Method Telomeres length Day 1 Telomeres length of circulating leukocytes
Genetic expression of p21, p53, H2Ax Day 1 Genetic expression of p21, p53, H2Ax of circulating leukocytes
Trial Locations
- Locations (1)
Centre Hospitalier Intercommunal de Créteil
🇫🇷Créteil, France